Exeter – Confidence in Concept 2019

Lead Research Organisation: UNIVERSITY OF EXETER
Department Name: UNLISTED

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The Confidence in Concept (CIC) scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions to flexibly support a portfolio of early stage translational research projects. CIC is designed to accelerate the transition from discovery research to viable translational projects by supporting preliminary studies to establish proof-of-concept so that the approach will then become competitive for more substantial translational funding.
 
Description A roadmap towards commercialisation of novel senotherapeutic technologies.
Geographic Reach National 
Policy Influence Type Contribution to new or improved professional practice
 
Description Launching the Citizen Phage Library as a national resource for adjunctive phage therapy.
Geographic Reach National 
Policy Influence Type Contribution to new or improved professional practice
Impact Provided evidence to the House of Commons Science and Technology committee regarding clinical use of bacteriophages.
 
Description Launching the Citizen Phage Library as a national resource for adjunctive phage therapy.
Geographic Reach National 
Policy Influence Type Contribution to new or improved professional practice
Impact Working with four UK hospitals to provide phages for patients and engaging with the MHRA to identify a route to use in the UK.
 
Description A preclinical drug screening platform for treatment-resistant depression
Amount £546,792 (GBP)
Funding ID MRC-MR/028972/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 12/2022 
End 12/2024
 
Description Innovate UK ICURe Follow on funding for A roadmap towards commercialisation of novel senotherapeutic technologies project
Amount £240,000 (GBP)
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 03/2021 
 
Description Launching the Citizen Phage Library as a national resource for adjunctive phage therapy.
Amount £50,000 (GBP)
Organisation Royal Devon and Exeter Hospital 
Sector Hospitals
Country United Kingdom
Start  
 
Description The zebrafish - a fast and reliable vertebrate model to study gene function to support target validation in the search for new human drug therapies.
Amount £600,000 (GBP)
Organisation AstraZeneca 
Sector Private
Country United Kingdom
Start  
 
Title A preclinical drug screening platform for treatment-resistant depression 
Description Establishment of a novel animal model for depression using a highly specific early life stress exposure in zebrafish 
Type Of Material Biological samples 
Year Produced 2021 
Provided To Others? No  
Impact Establishment of a novel animal model for depression using a highly specific early life stress exposure in zebrafish 
 
Title Launching the Citizen Phage Library as a national resource for adjunctive phage therapy 
Description We have developed improved methods to identify synergisms and antagonisms between phages and antibiotics during adjunctive therapies. Our new method captures both early-infection (chemical synergy) and late-infection (suppression of resistance) interactions. We have also developed methods to use kymographs and timelapse plaque assays to evaluate whether phages should be given to patients in combination or sequentially to maximise killing potential. 
Type Of Material Antibody 
Year Produced 2021 
Provided To Others? No  
Impact We have developed improved methods to identify synergisms and antagonisms between phages and antibiotics during adjunctive therapies. Our new method captures both early-infection (chemical synergy) and late-infection (suppression of resistance) interactions. We have also developed methods to use kymographs and timelapse plaque assays to evaluate whether phages should be given to patients in combination or sequentially to maximise killing potential. 
 
Title The zebrafish - a fast and reliable vertebrate model to study gene function to support target validation in the search for new human drug therapies. 
Description We have established stable transgenic zebrafish lines in which Cas9 protein expression is induced by chemical (doxycycline) exposure and the induction can be tracked by GFP fluorescence. Also, we have developed transgenic approach to express guide RNA (gRNA) specifically in the heart using zebrafish cmlc2 promoter and ribozyme RNA modification system. These tools will promote precise control of genome editing in heart tissue. 
Type Of Material Physiological assessment or outcome measure 
Year Produced 2023 
Provided To Others? No  
Impact We have established stable transgenic zebrafish lines in which Cas9 protein expression is induced by chemical (doxycycline) exposure and the induction can be tracked by GFP fluorescence. Also, we have developed transgenic approach to express guide RNA (gRNA) specifically in the heart using zebrafish cmlc2 promoter and ribozyme RNA modification system. These tools will promote precise control of genome editing in heart tissue. 
 
Title The zebrafish - a fast and reliable vertebrate model to study gene function to support target validation in the search for new human drug therapies. 
Description We have preliminary data generated supporting the usefulness of our system in spatiotemporal control of gene knock-out in zebrafish. Based on these encouraging data, we will further test and refine the system to make it applicable for AstraZeneca in target gene validation. 
Type Of Material Biological samples 
Year Produced 2021 
Provided To Others? No  
Impact We have preliminary data generated supporting the usefulness of our system in spatiotemporal control of gene knock-out in zebrafish. Based on these encouraging data, we will further test and refine the system to make it applicable for AstraZeneca in target gene validation. 
 
Title Launching the Citizen Phage Library as a national resource for adjunctive phage therapy 
Description From 137 Citizen Science samples we have isolated just over 200 new phages, of which ~90% have potential clinical use in phage therapy against three of the top six greatest threats of AMR globally. Genome analyses, host ranges etc will be made publically available shortly upon submission of the manuscripts being prepared. 
Type Of Material Data analysis technique 
Year Produced 2022 
Provided To Others? Yes  
Impact From 137 Citizen Science samples we have isolated just over 200 new phages, of which ~90% have potential clinical use in phage therapy against three of the top six greatest threats of AMR globally. Genome analyses, host ranges etc will be made publically available shortly upon submission of the manuscripts being prepared. 
 
Title Launching the Citizen Phage Library as a national resource for adjunctive phage therapy. 
Description Our phage library has now reached >800 phages. 
Type Of Material Database/Collection of data 
Year Produced 2023 
Provided To Others? No  
Impact Our phage library has now reached >800 phages. 
 
Description A preclinical drug screening platform for treatment-resistant depression 
Organisation Max Planck Society
Department Max Planck Institute of Psychiatry
Country Germany 
Sector Academic/University 
PI Contribution Collaboration was established with the Translational Research in Psychiatry group of Professor Elisabeth Binder, MD. PhD. Director of Max Planck Institute of Psychiatry in Munich, Germany. The goal is to determine whether the biomarkers that we had identified in our treatment-resistance depression zebrafish model are also found in human organoid system.
Collaborator Contribution Collaboration was established with the Translational Research in Psychiatry group of Professor Elisabeth Binder, MD. PhD. Director of Max Planck Institute of Psychiatry in Munich, Germany. The goal is to determine whether the biomarkers that we had identified in our treatment-resistance depression zebrafish model are also found in human organoid system.
Impact Collaboration was established with the Translational Research in Psychiatry group of Professor Elisabeth Binder, MD. PhD. Director of Max Planck Institute of Psychiatry in Munich, Germany. The goal is to determine whether the biomarkers that we had identified in our treatment-resistance depression zebrafish model are also found in human organoid system.
Start Year 2021
 
Description A roadmap towards commercialisation of novel senotherapeutic technologies. 
Organisation Medicines Discovery Catapult
Country United Kingdom 
Sector Private 
PI Contribution Both the above funders contributed financially along with SENISCA. Contributions from all parties = £265,000 ENISCA successfully engaged with the Medicines Discovery Catapult, who provided us with a roadmap around the emerging regulatory landscape for oligonucleotide biologics. We also used this funding to engage Yello Studios to provide us with marketing materials (pitch deck and website) which were key to our successful equity fundraising. Collaboration with Murdoch University (Perth, Aus), where SENISCA has an embedded member of staff and member of our Scientific Advisory Board. We are also in the final stages of negotiation towards signing our first commercial co-development deal with a large US-based cosmetics corporate for our skin aesthetics arm.
Collaborator Contribution Both the above funders contributed financially along with SENISCA. Contributions from all parties = £265,000 ENISCA successfully engaged with the Medicines Discovery Catapult, who provided us with a roadmap around the emerging regulatory landscape for oligonucleotide biologics. We also used this funding to engage Yello Studios to provide us with marketing materials (pitch deck and website) which were key to our successful equity fundraising. Collaboration with Murdoch University (Perth, Aus), where SENISCA has an embedded member of staff and member of our Scientific Advisory Board. We are also in the final stages of negotiation towards signing our first commercial co-development deal with a large US-based cosmetics corporate for our skin aesthetics arm.
Impact Both the above funders contributed financially along with SENISCA. Contributions from all parties = £265,000 ENISCA successfully engaged with the Medicines Discovery Catapult, who provided us with a roadmap around the emerging regulatory landscape for oligonucleotide biologics. We also used this funding to engage Yello Studios to provide us with marketing materials (pitch deck and website) which were key to our successful equity fundraising. Collaboration with Murdoch University (Perth, Aus), where SENISCA has an embedded member of staff and member of our Scientific Advisory Board. We are also in the final stages of negotiation towards signing our first commercial co-development deal with a large US-based cosmetics corporate for our skin aesthetics arm.
Start Year 2021
 
Description A roadmap towards commercialisation of novel senotherapeutic technologies. 
Organisation Murdoch University
Country Australia 
Sector Academic/University 
PI Contribution Both the above funders contributed financially along with SENISCA. Contributions from all parties = £265,000 ENISCA successfully engaged with the Medicines Discovery Catapult, who provided us with a roadmap around the emerging regulatory landscape for oligonucleotide biologics. We also used this funding to engage Yello Studios to provide us with marketing materials (pitch deck and website) which were key to our successful equity fundraising. Collaboration with Murdoch University (Perth, Aus), where SENISCA has an embedded member of staff and member of our Scientific Advisory Board. We are also in the final stages of negotiation towards signing our first commercial co-development deal with a large US-based cosmetics corporate for our skin aesthetics arm.
Collaborator Contribution Both the above funders contributed financially along with SENISCA. Contributions from all parties = £265,000 ENISCA successfully engaged with the Medicines Discovery Catapult, who provided us with a roadmap around the emerging regulatory landscape for oligonucleotide biologics. We also used this funding to engage Yello Studios to provide us with marketing materials (pitch deck and website) which were key to our successful equity fundraising. Collaboration with Murdoch University (Perth, Aus), where SENISCA has an embedded member of staff and member of our Scientific Advisory Board. We are also in the final stages of negotiation towards signing our first commercial co-development deal with a large US-based cosmetics corporate for our skin aesthetics arm.
Impact Both the above funders contributed financially along with SENISCA. Contributions from all parties = £265,000 ENISCA successfully engaged with the Medicines Discovery Catapult, who provided us with a roadmap around the emerging regulatory landscape for oligonucleotide biologics. We also used this funding to engage Yello Studios to provide us with marketing materials (pitch deck and website) which were key to our successful equity fundraising. Collaboration with Murdoch University (Perth, Aus), where SENISCA has an embedded member of staff and member of our Scientific Advisory Board. We are also in the final stages of negotiation towards signing our first commercial co-development deal with a large US-based cosmetics corporate for our skin aesthetics arm.
Start Year 2021
 
Description A roadmap towards commercialisation of novel senotherapeutic technologies. 
Organisation Senisca Ltd
Country United Kingdom 
Sector Private 
PI Contribution We have discovered a new molecular mechanism by which cells become senescent, which can be targeted for reversal of senescence and rejuvenation of cell function. Furthermore, we have identified several points of intervention, and obtained proof of principle data from several disease-relevant human cell types that senescence can be reversed. Our data show that this approach is feasible and can form the basis for a new generation of treatments for age-related disease
Collaborator Contribution Our Associates Paul Edwards and Kirsty Semple of SENISCA will provide their time (£500/day) as in-kind contribution (~£10,000). KS and PE are two experienced start up consultants with commercial and medicinal chemistry experience to aid with development of pre- and post-incorporation materials as well as investment marketing materials that will be presented to investors at suitable events throughout the rest of 2020/21.
Impact Suuceesful application for £39,575.00 MRC Confidence in concept
Start Year 2020
 
Description Launching the Citizen Phage Library as a national resource for adjunctive phage therapy. 
Organisation Defence Science & Technology Laboratory (DSTL)
Country United Kingdom 
Sector Public 
PI Contribution Collaborating with DSTL to develop phage therapeutics for Coxiella. Collaborating with Singer Instruments to develop optimised plaque picking with machine learning to improve selection of plaques for downstream processing. Collaborating with the Environment Agency to screen national wastewater samples for potential therapeutic phages. Partnership with Dann Turner at UWE to work on Acietobacter baumannii phages.
Collaborator Contribution Collaborating with DSTL to develop phage therapeutics for Coxiella. Collaborating with Singer Instruments to develop optimised plaque picking with machine learning to improve selection of plaques for downstream processing. Collaborating with the Environment Agency to screen national wastewater samples for potential therapeutic phages. Partnership with Dann Turner at UWE to work on Acietobacter baumannii phages.
Impact Collaborating with DSTL to develop phage therapeutics for Coxiella. Collaborating with Singer Instruments to develop optimised plaque picking with machine learning to improve selection of plaques for downstream processing. Collaborating with the Environment Agency to screen national wastewater samples for potential therapeutic phages. Partnership with Dann Turner at UWE to work on Acietobacter baumannii phages.
Start Year 2021
 
Description Launching the Citizen Phage Library as a national resource for adjunctive phage therapy. 
Organisation Environment Agency
Country United Kingdom 
Sector Public 
PI Contribution Collaborating with DSTL to develop phage therapeutics for Coxiella. Collaborating with Singer Instruments to develop optimised plaque picking with machine learning to improve selection of plaques for downstream processing. Collaborating with the Environment Agency to screen national wastewater samples for potential therapeutic phages. Partnership with Dann Turner at UWE to work on Acietobacter baumannii phages.
Collaborator Contribution Collaborating with DSTL to develop phage therapeutics for Coxiella. Collaborating with Singer Instruments to develop optimised plaque picking with machine learning to improve selection of plaques for downstream processing. Collaborating with the Environment Agency to screen national wastewater samples for potential therapeutic phages. Partnership with Dann Turner at UWE to work on Acietobacter baumannii phages.
Impact Collaborating with DSTL to develop phage therapeutics for Coxiella. Collaborating with Singer Instruments to develop optimised plaque picking with machine learning to improve selection of plaques for downstream processing. Collaborating with the Environment Agency to screen national wastewater samples for potential therapeutic phages. Partnership with Dann Turner at UWE to work on Acietobacter baumannii phages.
Start Year 2021
 
Description Launching the Citizen Phage Library as a national resource for adjunctive phage therapy. 
Organisation Singer Instruments
Country United Kingdom 
Sector Private 
PI Contribution Collaborating with DSTL to develop phage therapeutics for Coxiella. Collaborating with Singer Instruments to develop optimised plaque picking with machine learning to improve selection of plaques for downstream processing. Collaborating with the Environment Agency to screen national wastewater samples for potential therapeutic phages. Partnership with Dann Turner at UWE to work on Acietobacter baumannii phages.
Collaborator Contribution Collaborating with DSTL to develop phage therapeutics for Coxiella. Collaborating with Singer Instruments to develop optimised plaque picking with machine learning to improve selection of plaques for downstream processing. Collaborating with the Environment Agency to screen national wastewater samples for potential therapeutic phages. Partnership with Dann Turner at UWE to work on Acietobacter baumannii phages.
Impact Collaborating with DSTL to develop phage therapeutics for Coxiella. Collaborating with Singer Instruments to develop optimised plaque picking with machine learning to improve selection of plaques for downstream processing. Collaborating with the Environment Agency to screen national wastewater samples for potential therapeutic phages. Partnership with Dann Turner at UWE to work on Acietobacter baumannii phages.
Start Year 2021
 
Description Launching the Citizen Phage Library as a national resource for adjunctive phage therapy. 
Organisation University of the West of England
Country United Kingdom 
Sector Academic/University 
PI Contribution Collaborating with DSTL to develop phage therapeutics for Coxiella. Collaborating with Singer Instruments to develop optimised plaque picking with machine learning to improve selection of plaques for downstream processing. Collaborating with the Environment Agency to screen national wastewater samples for potential therapeutic phages. Partnership with Dann Turner at UWE to work on Acietobacter baumannii phages.
Collaborator Contribution Collaborating with DSTL to develop phage therapeutics for Coxiella. Collaborating with Singer Instruments to develop optimised plaque picking with machine learning to improve selection of plaques for downstream processing. Collaborating with the Environment Agency to screen national wastewater samples for potential therapeutic phages. Partnership with Dann Turner at UWE to work on Acietobacter baumannii phages.
Impact Collaborating with DSTL to develop phage therapeutics for Coxiella. Collaborating with Singer Instruments to develop optimised plaque picking with machine learning to improve selection of plaques for downstream processing. Collaborating with the Environment Agency to screen national wastewater samples for potential therapeutic phages. Partnership with Dann Turner at UWE to work on Acietobacter baumannii phages.
Start Year 2021
 
Description The zebrafish - a fast and reliable vertebrate model to study gene function to support target validation in the search for new human drug therapies. 
Organisation AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution Parnership with AstraZeneca is growing and an UKRI funding was granted for the genome editing project (see Further Funding section). We also had one-day in-person meeting with AstaraZeneca drug discovery team in Exeter in October 2022 to discuss further collaboration. BSRC Indutrial Partnership Award (BBSRC-IPA) was awarded to the collaboration project with AstraZeneca "Establishing precise genome editing in zebrafish and its application to advance understanding of the Wnt/PCP signalling pathway" (PI: Steffen Scholpp, CoI: Charles Tyler, RcoI: Yosuke Ono). In the 3-years project, we will apply an advanced CRISPR/Cas9-based genome editing technology in zebrafish model. £600,000 was funded by BBSRC and AstraZeneca.
Collaborator Contribution Parnership with AstraZeneca is growing and an UKRI funding was granted for the genome editing project (see Further Funding section). We also had one-day in-person meeting with AstaraZeneca drug discovery team in Exeter in October 2022 to discuss further collaboration. BSRC Indutrial Partnership Award (BBSRC-IPA) was awarded to the collaboration project with AstraZeneca "Establishing precise genome editing in zebrafish and its application to advance understanding of the Wnt/PCP signalling pathway" (PI: Steffen Scholpp, CoI: Charles Tyler, RcoI: Yosuke Ono). In the 3-years project, we will apply an advanced CRISPR/Cas9-based genome editing technology in zebrafish model. £600,000 was funded by BBSRC and AstraZeneca.
Impact Parnership with AstraZeneca is growing and an UKRI funding was granted for the genome editing project (see Further Funding section). We also had one-day in-person meeting with AstaraZeneca drug discovery team in Exeter in October 2022 to discuss further collaboration. BSRC Indutrial Partnership Award (BBSRC-IPA) was awarded to the collaboration project with AstraZeneca "Establishing precise genome editing in zebrafish and its application to advance understanding of the Wnt/PCP signalling pathway" (PI: Steffen Scholpp, CoI: Charles Tyler, RcoI: Yosuke Ono). In the 3-years project, we will apply an advanced CRISPR/Cas9-based genome editing technology in zebrafish model. £600,000 was funded by BBSRC and AstraZeneca.
Start Year 2021
 
Title A roadmap towards commercialisation of novel senotherapeutic technologies. 
Description Background patent now transferred to SENISCA Ltd following reaching assignment trigger of £2m capital raised. 
IP Reference  
Protection Patent / Patent application
Year Protection Granted 2023
Licensed Yes
Impact Background patent now transferred to SENISCA Ltd following reaching assignment trigger of £2m capital raised.
 
Title Launching the Citizen Phage Library as a national resource for adjunctive phage therapy. 
Description We have now supplied phages to four countries for compassionate use. 
Type Preventative Intervention - Physical/Biological risk modification
Current Stage Of Development Small-scale adoption
Year Development Stage Completed 2023
Development Status Under active development/distribution
Impact We have now supplied phages to four countries for compassionate use. 
 
Title Treatment of 10 year old with cystic fibrosis/Pseudomonas aeruginosa. 
Description We were asked through PhageDirectory to supply phages that could treat a 10 year old cystic fibrosis patient in Switzerland with a pan-resistant strain of Pseudomonas aeruginosa. Within three days of receiving the strain we had identified three phages that were clinically suitable from our citizen science samples. These phages have since been screened and trained to reduce emergence of resistance in the patient. Phages will be shipped to Switzerland in April to begin treatment in May. 
Type Therapeutic Intervention - Vaccines
Year Development Stage Completed 2021
Development Status Closed
Impact We were asked through PhageDirectory to supply phages that could treat a 10 year old cystic fibrosis patient in Switzerland with a pan-resistant strain of Pseudomonas aeruginosa. Within three days of receiving the strain we had identified three phages that were clinically suitable from our citizen science samples. These phages have since been screened and trained to reduce emergence of resistance in the patient. Phages will be shipped to Switzerland in April to begin treatment in May. 
 
Title Open-source infrastructure for hosting a Citizen Phage Library portal website 
Description Open-source infrastructure for hosting a Citizen Phage Library portal website that captures metadata from samples. 
Type Of Technology New/Improved Technique/Technology 
Year Produced 2021 
Impact Open-source infrastructure for hosting a Citizen Phage Library portal website that captures metadata from samples. 
 
Company Name SENISCA LTD 
Description SENISCA Ltd. Spun out from University of Exeter in Oct 20. Currently at 10x FTE positions in UK with a further 0.5x FTE position embedded in labs at Murdoch University. 
Year Established 2020 
Impact SENISCA Ltd. Spun out from University of Exeter in Oct 20. Currently at 10x FTE positions in UK with a further 0.5x FTE position embedded in labs at Murdoch University.
 
Description Article in The Biologist re Launching the Citizen Phage Library as a national resource for adjunctive phage therapy project 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact wrote an article in The Biologist, which gained significant readership and led to recruitment of phage hunters from across the globe. (https://thebiologist.rsb.org.uk/biologist-features/hunting-for-holes-of-hope)
Year(s) Of Engagement Activity 2021
 
Description Established the citizenphage portal (https://citizenphage.com) re Launching the Citizen Phage Library as a national resource for adjunctive phage therapy project 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Established the citizenphage portal (https://citizenphage.com) to recruit citizen scientists.
Year(s) Of Engagement Activity 2021
 
Description Launching the Citizen Phage Library as a national resource for adjunctive phage therapy. 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Schools
Results and Impact Completed two outreach events at schools, one public outreach event on water quality, and a public outreach event at Torbay Museum.
Year(s) Of Engagement Activity 2023
 
Description Live chat for Performed a livestreamed "Fireside Chat" on World Phage Day re Launching the Citizen Phage Library as a national resource for adjunctive phage therapy 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact Performed a livestreamed "Fireside Chat" on World Phage Day to discuss the Citizen Phage Library project through the Exeter Science Centre facebook page
Year(s) Of Engagement Activity 2021
 
Description Media interview for New Scientist re Launching the Citizen Phage Library as a national resource for adjunctive phage therapy 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact Was approached for comment by reporter for New Scientist on phage therapy, following a discussion on our work https://institutions.newscientist.com/article/2304997-phage-therapies-for-superbug-infections-are-being-tested-in-belgium/
Year(s) Of Engagement Activity 2021
 
Description Outreach event - Sidmouth Science Festival 2021 re Launching the Citizen Phage Library as a national resource for adjunctive phage therapy. 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Outreach event at Sidmouth Science Festival in 2021 to discuss AMR with the general public.
Year(s) Of Engagement Activity 2021
 
Description Transdisciplinary colloquium on psychedelics at Exeter re Detecting identity shifts in addiction treatment with KARE therapy project 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Other audiences
Results and Impact Set up transdisciplinary colloqiuim on psychedelics at Exeter
Year(s) Of Engagement Activity 2021
 
Description Visited four primary and secondary schools in the SouthWest re Launching the Citizen Phage Library as a national resource for adjunctive phage therapy project 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Schools
Results and Impact Visited four primary and secondary schools in the SouthWest to talk about phage therapy and AMR with Years 10-11 pupils (>150 pupils total) re Launching the Citizen Phage Library as a national resource for adjunctive phage therapy project.
Year(s) Of Engagement Activity 2021